Minneapolis, MN — Cargill, Inc. and Evolva Holding SA’s development of fermentation-based steviol glycosides is ahead of schedule, as the project moves into pilot phase this year instead of 2014.
The news resulted in a 9.2 percent price increase in Evolva’s shares on the Swiss exchange Monday. The partners, who entered into a development agreement earlier this year, expect the fermentation-based steviol glycosides, the compounds responsible for the sweet taste of stevia plant leaves, to benefit food and beverage manufacturers by enabling cost-effective, commercially relevant sweetening solutions.
David Henstrom, Cargill Corn Milling North America global business director for health ingredients, explains: “The stevia market is focused on understanding the subtleties of how different steviol glycosides interact to create the most pleasing sweetness profile. This technology complements Cargill’s existing and forthcoming innovations in stevia-based sweeteners.”